Diabetes news 2006-09

2006-09-17 Eighth Annual Novartis Prize In Diabetes Award Recipients Announced

In the recent past diabetes organisations thought that glucose tolerance tests were not usually necessary in order to diagnose diabetes. In one of the earliest examinations of the new category of impaired fasting glucose, Professor Jonathan Shaw, Deputy Director, International Diabetes Institute, Melbourne, Australia, questioned the validity of the lower threshold of the category, and suggested that a lower value would be more consistent with available data1. In what was to become a key area of international dispute over later years, Dr. Shaw analysed the impact of the ADAs recommendation that the oral glucose tolerance test was not usually necessary for the diagnosis of diabetes. In a key paper, Professor Shaw demonstrated that the post-challenge glucose value was a stronger predictor of mortality than was the fasting glucose, and

www.medicalnewstoday.com

Four recipients of the eighth annual Novartis Prize in Diabetes were honoured for their significant achievements in researching diabetes risk and management during the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen to 17, 2006 - Diabetes news medical news health news medical headlines healthcare news health articles medicine articles welfare living

2006-09-15 PharmaLive: Novartis Announces Recipients of Eighth Annual Novartis Prize in Diabetes Award

In the recent past diabetes organisations thought that glucose tolerance tests were not usually necessary in order to diagnose diabetes. In one of the earliest examinations of the new category of impaired fasting glucose, Professor Jonathan Shaw, Deputy Director, International Diabetes Institute, Melbourne, Australia, questioned the validity of the lower threshold of the category, and suggested that a lower value would be more consistent with available data1. In what was to become a key area of international dispute over later years, Dr. Shaw analysed the impact of the ADA and rsquo;s recommendation that the oral glucose tolerance test was not usually necessary for the diagnosis of diabetes. In a key paper, Professor Shaw demonstrated that the post-challenge glucose value was a stronger predictor of mortality than was the fasting

www.medadnews.com

2006-09-13 One in Three Parents Surveyed Unaware of Easy Ketone Test That May Help Prevent the Onset of Diabetic Ketoacidosis (DKA)

Frequent Testing Reduces Hospitalization for Life Threatening Condition ALAMEDA, Calif. , Sept. 13 /PRNewswire-FirstCall/ -- Survey findings announced today by Abbott and Children with Diabetes (CWD) indicate that more than one third of parents of children with type 1 diabetes are unaware of an at-home blood ketone test which may help prevent the onset or progression of Diabetic Ketoacidosis (DKA), commonly known as diabetic coma. DKA is a life- threatening condition and is the leading cause of mortality among children with diabetes. Ketones are substances formed in the blood when fat is broken down for energy because of insufficient insulin levels. Severe insulin deficiency and high blood ketone levels result in DKA. Frequent testing for ketones during times of illness, when the risk of ketone development is notably higher,

www.prnewswire.com

2006-09-12 JDRF Announces New Research Grants to Accelerate the Availability of an Artificial Pancreas: Financial News - Yahoo. Finance

The Continuous Glucose Sensor Human Clinical Trial will invite nine research centers each using the same clinical protocol. These sites will test the effectiveness of sensors in various populations (including children and adults of various ethnic and socioeconomic groups) and different health care settings (including specialty diabetes care, managed care, and publicly funded clinics). The trial will specifically investigate whether continuous glucose sensors have a direct impact on better glycemic control, reduced HbA1c levels, and hypoglycemia. But it will also explore the impact of sensors on other aspects of diabetes care, such as quality of life issues, for the children using the devices, as well as their parents. The selected researchers include:

biz.yahoo.com

JDRF Announces New Research Grants to Accelerate the Availability of an Artificial Pancreas. - NEW YORK, Sept. 12 /PRNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of type 1 diabetes research, announced today that it has funded leading researchers from around the world to assess new diabetes technologies and help accelerate their availability

2006-09-14 Breaking News: Human Genetic Testing Center Receives International Quality Accreditation in Germany; IntegraGen Awarded ISO 17025 Accreditation for Its Molecular Diagnostics Center in Bonn

Germany currently has some of the highest levels of diabetes in the world, having 6. 3 million people affected by it according to the International Diabetes Federation. Genes for most of the monogenic hereditary forms of the disease have been identified and IntegraGen offers tests for these including: MODY (Maturity Onset Diabetes of the Young); Mitochondrial Diabetes; Neonatal Diabetes: and Congenital hyperinsulinism. Accurate identification of the mutation causing the diabetes has considerable advantages for the patient and helps direct the correct drug treatment or intervention. IntegraGen is also developing a number of additional tests for other genes that are linked to the development of diabetes.

www.genengnews.com

Breaking News: Human Genetic Testing Center Receives International Quality Accreditation in Germany; IntegraGen Awarded ISO 17025 Accreditation for Its Molecular Diagnostics Center in Bonn. Genetic Engineering News is the most widely read bioindustry publication worldwide and has long been acknowledged as the voice of the global biotechnology bioindustry. - Biotechnology Bioindustry Drug Discovery Bioprocessing Bioscience

2006-09-12 Defective Blood Glucose Meters Lead to Class 1 Diabetic Meter Recalls

In the last two years, The Food and Drug Administration has issued more than 20 different Class I High Risk recalls for diabetic test meters. Class I recalls are for dangerous or defective products that predictably could cause serious health problems or death. Because of potential electronic malfunction, many of the recalled diabetic test meters could fail or provide false results, leading to possible mismanagement of the disease. For consumers with Medicare or qualifying private insurance, American Diabetes Services can replace defective meters with new diabetic test meters for no or very low cost(s) to the consumer.

www.prweb.com

PR: Diabetics cautioned about inaccurate diabetic test meter results. Boca Raton, FL (PRWEB) - Every day millions of diabetics rely on their blood glucose meters as an accurate gauge to help manage their diabetes. But what if that reading was wrong With several http://www. americandi

2006-09-17 To beat back diabetes, were the ones - The Boston Globe

This rather bold contention -- that we can serve as a model for effective chronic disease management in low-income, urban communities -- is about to be put to the test. The Richard and Susan Smith Family Foundation and the Paul and Phyllis Fireman Charitable Foundation recently partnered to award our five health centers a combined usd. 5. 05 million over five years to pay for the case management, diabetes education, lifestyle coaching, and community outreach programs that we have not been able to adopt on the scale needed -- until now, that is.

www.boston.com

2006-09-15 UCLA neuroscience research leads to a possible treatment

To study the possible connection between GAD and diabetes, Kaufman again worked with Tobin and Erlander, using the research tools they had developed to test whether autoantibodies against GAD could be found in frozen blood samples taken from individuals before they developed type 1 diabetes. They found that they could detect autoantibodies against GAD years before the symptoms of diabetes appeared.

A new vaccine being tested in a human clinical trial holds a great deal of promise for treating type 1 diabetes, a disease that newly afflicts 35,000 children each year. The research that established the foundation for this vaccine was conducted in UCLA research laboratories. The drug is still being tested and is not likely to be available for at least a few years.

www.newsroom.ucla.edu

News and special communications from UCLA, including press releases from the Office of Media Relations, news bulletins, advisories and tips. - UCLA press releases UCLA in the news UCLA headlines UCLA Office of Media Relations University of California Los Angeles

2006-10-02 The Assembly Top 50 - Cover Story - ASSEMBLY

Abbott ranks third in the market for blood glucose monitoring equipment. The company tallied more than usd. 1 million in sales of the devices worldwide in 2005, an increase of nearly 35 percent from 2004. Moreover, two products in the late stages of development could soon help the company increase its market share and significantly improve care for patients with diabetes. Awaiting FDA approval is the FreeStyle Navigator, a new continuous glucose monitoring system. Designed to measure patient glucose levels as frequently as once per minute, 24 hours per day, the device features a sensor worn on the body that wirelessly transmits readings every minute to a pager-like device kept in a pocket or purse. Also in development is a fully integrated blood glucose monitor that combines both test strips and lancing capabilities in one device,

www.assemblymag.com

2006-10-02 Federal Economic Development Agency Launches Innovative Health Care Initiative In Eight Delta States

Callers speak to a diabetes specialist, are given a free diabetes risk test, screened for Medicaid eligibility, given help finding a doctor and plugged into other diabetes education and management resources in their area. The media outreach will be combined with community, minority and grassroots outreach plans to bring the message about taking control of ones diabetes to hard-to-reach segments of the population.

Each person who calls the toll free number, 1-866-602-3300, or visits the Healthy Delta website, , will be contacted again for follow up at - and 120- day intervals to track progress and see if the caller visited a health care provider or diabetes education center. Based on data collected by the call center, the DRA is building a database to demonstrate measurable outcomes in diabetes management in the Delta region. Also present at the announcement was Larry Smith, national chair of the American Diabetes Association. Smith discussed ADAs support for Healthy Delta.

www.medicalnewstoday.com

The Delta Regional Authority unveiled a new program today built on the concept of using health as an economic engine - Diabetes news medical news health news medical headlines healthcare news health articles medicine articles welfare living